MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

Bookmark and Share
Published: 20 Jun 2019
Views: 1580
Dr Johannes Düll - University of Würzburg, Würzburg, Germany

Dr Johannes Düll speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the results from his trial of MOR208 plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.